Literature DB >> 2470994

Vascular effects of carvedilol, a new beta-adrenoceptor antagonist with vasodilating properties, in isolated canine coronary artery.

Y Hattori1, H Nakaya, M Endou, Y Nakao, M Kanno.   

Abstract

The pharmacologic properties of carvedilol, a beta-adrenoceptor antagonist with vasodilating activity, were investigated in isolated canine coronary artery ring preparations. Carvedilol competitively antagonized the relaxations caused by isoproterenol in 40 mM K+-depolarized preparations and its pA, value was 9.70 +/- 0.08. At concentrations greater than or equal to 3 x 10(-6) M, carvedilol significantly inhibited the contractile response to high [K+]o. Compared with the inhibitory effect on the KCl-induced contraction, the drug was less effective in suppressing the contraction induced by prostaglandin F2 alpha (PGF2 alpha). In addition, carvedilol (10(-7) to 3 x 10(-5) M) suppressed the contraction produced by Bay K 8644, a Ca2+ channel agonist. The concentration-response curve for Bay K 8644 was shifted downward by carvedilol in a concentration-dependent manner. The drug also produced a concentration-dependent inhibitory effect on the 4-aminopyridine-induced rhythmic contractions in a similar fashion to the Ca2+ channel antagonists. Carvedilol was ineffective in suppressing the contractions induced by PGF2 alpha in Ca2+-free solution and by A-23187. The results suggest that carvedilol exerts a vasodilating action possibly by inhibiting Ca2+ influx through potential-operated Ca2+ channels, although the concentrations required for producing the vasodilation are much higher than that for the beta-adrenoceptor antagonism in canine coronary artery.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470994

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

Review 1.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

2.  Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans.

Authors:  Rahmatina B Herman; Peter J Jesudason; Ali M Mustafa; Ruby Husain; Anna Maria J Choy; Chim C Lang
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

Review 3.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 4.  Pharmacological profile of beta-adrenoceptor blockers with vasodilating properties, especially carvedilol--rationale for clinical use.

Authors:  G Sponer; W Bartsch; K Strein
Journal:  Clin Investig       Date:  1992

5.  Clinical pharmacology of carvedilol.

Authors:  B Tomlinson; B N Prichard; B R Graham; R J Walden
Journal:  Clin Investig       Date:  1992

6.  Effects of carvedilol on common carotid arterial flow, peripheral hemodynamics, and hemorheologic variables in hypertension.

Authors:  Y Nagakawa; Y Akedo; S Kaku; H Orimo
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Hemodynamic differences between carvedilol and labetalol in the cutaneous circulation.

Authors:  R R Ruffolo; C F Sauermelch; R N Willette
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

8.  Effects of carvedilol on serum lipids in hypertensive and normotensive subjects.

Authors:  H Seguchi; H Nakamura; N Aosaki; Y Homma; Y Mikami; S Takahashi
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.